Physician perspectives on the burden and management of asthma in six countries: The Global Asthma Physician Survey (GAPS)

Chapman, Kenneth R.; Hinds, David; Piazza, Peter; Raherison, Chantal; Gibbs, Michael; Greulich, Timm; Gaalswyk, Kenneth; Lin, Jiangtao; Adachi, Mitsuru; Davis, Kourtney J.

doi:10.1186/s12890-017-0492-5

Table 4 Physicians’ perspectives on MART

From: Physician perspectives on the burden and management of asthma in six countries: The Global Asthma Physician Survey (GAPS)

% of physicians giving response	Total n=1286	Canada n=248	France n=112	Germany n=180	Australia n=269	China n=281	Japan n=196
Reasons for prescribing MART
Patients with severe symptoms (daytime/night-time symptoms ≥4 days/week)	35	3	15	11	1	79	3
Patients with moderate symptoms (daytime/night-time symptoms 2–3 days/week)	33	5	16	10	1	72	6
Patients with/at risk of exacerbations	30	7	12	5	9	51	29
Greater convenience for the patient as only one inhaler is required	22	27	32	15	28	29	6
Patient factors (knowledge/understanding, compliance, age)	20	54	5	17	65	-	29
Reasons for not prescribing MART^a
Patients with more mild symptoms	38	10	8	4	13	64	6
Patients with poor adherence	25	13	34	18	18	29	18
Patients with severe symptoms (daytime/night-time symptoms ≥4 days/week)	19	14	14	17	18	25	5
Patients with lots of co-morbidities	14	18	3	16	16	15	10
Patient factors (knowledge/understanding, compliance, age)	10	30	14	10	37	-	21
Prescription of SABA/bronchodilator with MART
Always	19	13	27	10	6	33	3
Most of the time	30	19	29	29	23	42	18
Some of the time	42	55	37	52	50	23	63
Never	8	13	7	9	21	1	13
Reasons for prescribing SABAs / bronchodilators with MART^b
Patients want an extra reliever to feel safer	35	14	28	36	14	59	8
Patient familiarity with short-acting-beta medicine	32	19	13	13	18	59	8
Patient convenience – having an extra reliever on hand	27	4	13	5	3	56	2
Patients are accustomed to having an extra reliever	20	5	19	6	6	35	8
MART dosing instructions provided to pharmacy
Don’t write anything different to normal dosing	32	25	10	29	23	38	37
Write Maintenance Plus Reliever language as a standard choice	26	19	27	8	18	41	15
Have to create my own text noting maintenance frequency and PRN	21	35	54	33	36	1	24
Write ICS/LABA as both maintenance and reliever	15	18	7	13	20	16	17
MART dosing instructions provided to patients
Verbal instructions to use the ICS/LABA as relief as well as maintenance	87	89	91	83	73	93	82
Written instructions to use the ICS/LABA as relief as well as maintenance	59	45	84	81	66	71	24
Verbal instructions to use the ICS/LABA as relief but not maintenance	14	7	36	20	6	16	6
Written instructions to use the ICS/LABA as relief but not maintenance	6	4	30	18	3	1	1
Time/effort required for MART prescribing vs. other maintenance medications^c
Much more time and effort	14	4	1	6	5	24	11
Somewhat more time and effort	40	32	21	38	40	45	42
About the same	29	38	68	43	29	19	20
Somewhat less time and effort	13	19	9	9	18	7	21
Much less time and effort	5	7	0	4	7	5	6

Questions regarding MART administration were asked only of physicians who had prescribed MART. ‘-’ represents values of 0% or <1%. For questions with more than five possible responses, the five reasons with the highest overall response rates (with overall response rates of ≥10%) have been included. Percentage values within categories may sum to <100% or >100% due to rounding and weightings applied
ICS inhaled corticosteroid, LABA long-acting β₂-agonist, MART maintenance and reliever therapy, PRN pro re nata (as needed), SABA short-acting β₂-agonist
^aAmong physicians responding yes to there being situations where MART would not be prescribed: Total (n=805), Canada (n=151), France (n=70), Germany (n=93), Australia (n=157), China (n=259), Japan (n=75); ^bAmong physicians reporting prescribing SABA with MART some of the time, most of the time, or always: Total (n=1127), Canada (n=211), France (n=104), Germany (n=165), Australia (n=209), China (n=277), Japan (n=161); ^cExcluding physicians responding ‘Don’t know’ or ‘Refuse’: Total (n=1283), Canada (n=248), France (n=112), Germany (n=179), Australia (n=269), China (n=281), Japan (n=194)

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Pulmonary Medicine

Contact us